COVID-19 - Resources GIST Patients Need - Please know that the Life Raft Group is here to support you during this Coronavirus crisis. We will continue our daily services during this time and we will be distributing information and messages of hope through all our communication channels.
During this health epidemic, wondering about being immunocompromised is a valid concern for GIST patients whether NED or on treatment and best practices are outlined in this post as quoted by experts in cancer patient treatment.
You probably are very aware of the anxiety you are feeling since the onset of the COVID-19 pandemic. What you may not be aware of is the other emotion that has been weighing heavily on most of us these days: grief.
These are trying times for everyone. As we move into uncharted territory created by the coronavirus pandemic, it is normal for the average person to experience fearful thoughts. Add to the mix fears that are ever present for those with a cancer diagnosis and you have a formula for anxiety.
Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.
Director of Communications Mary Garland shares these top ten tips for caregivers for this GIST journey.
2020 is here, and 'It’s Time' to get ready for Life Fest in New Orleans. To kick off the celebration, here are 20 compelling reasons for you to join us in New Orleans for Life Fest 2020!
Our Rare Disease Day offering is a whitepaper titled 'Partnership for Survival – Treating the Rarest of the Rare' detailing how a collaboration with the NIH has become a model for other advocacy groups and researchers.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.